Secretory Phospholipase A2-IIA and Cardiovascular Disease A Mendelian Randomization Study

Citation for published version: Holmes, MV, Simon, T, Exeter, HJ, Folkersen, L, Asselbergs, FW, Guardiola, M, Cooper, JA, Palmen, J, Hubacek, JA, Carruthers, KF, Horne, BD, Brunisholz, KD, Mega, JL, Van Iperen, EPA, Li, M, Leusink, M, Trompet, S, Verschuren, JJW, Hovingh, GK, Dehghan, A, Nelson, CP, Kotti, S, Danchin, N, Scholz, M, Haase, CL, Rothenbacher, D, Swerdlow, DI, Kuchenbaecker, KB, Staines-Urias, E, Goel, A, van 't Hooft, F, Gertow, K, de Faire, U, Panayiotou, AG, Tremoli, E, Baldassarre, D, Veglia, F, Holdt, LM, Beutner, F, Gansevoort, RT, Navis, GJ, Leach, IM, Breitling, LP, Brenner, H, Thiery, J, Dallmeier, D, Franco-Cereceda, A, Boer, JMA, Stephens, JW, Hofker, MH, Tedgui, A, Hofman, A, Uitterlinden, AG, Adamkova, V, Pitha, J, Onland-Moret, NC, Cramer, MJ, Nathoe, HM, Spiering, W, Klungel, OH, Kumari, M, Whincup, PH, Morrow, DA, Braund, PS, Hall, AS, Olsson, AG, Doevendans, PA, Trip, MD, Tobin, MD, Hamsten, A, Watkins, H, Koenig, W, Nicolaides, AN, Teupser, D, Day, INM, Carlquist, JF, Gaunt, TR, Ford, I, Sattar, N, Tsimikas, S, Schwartz, GG, Lawlor, DA, Morris, RW, Sandhu, MS, Poledne, R, Maitland-van der Zee, AH, Khaw, K-T, Keating, BJ, van der Harst, P, Price, JF, Mehta, SR, Yusuf, S, Witteman, JCM, Franco, OH, Jukema, JW, de Knijff, P, Tybjaerg-Hansen, A, Rader, DJ, Farrall, M, Samani, NJ, Kivimaki, M, Fox, KAA, Humphries, SE, Anderson, JL, Boekholdt, SM, Palmer, TM, Eriksson, P, Pare, G, Hingorani, AD, Sabatine, MS, Mallat, Z, Casas, JP & Talmud, PJ 2013, 'Secretory Phospholipase A2-IIA and Cardiovascular Disease: A Mendelian Randomization Study' Journal of the American College of Cardiology, vol 62, no. 21, pp. 19661976. DOI: 10.1016/j.jacc.2013.06.044

Tom R. Gaunt | O. Franco | A. Uitterlinden | M. Tobin | D. Lawlor | Mingyao Li | S. Yusuf | J. Boer | J. Mega | B. Horne | N. Samani | A. Hall | P. Braund | M. Farrall | J. Carlquist | A. Hingorani | M. Sabatine | A. Dehghan | D. Rader | M. Guardiola | P. Talmud | P. Whincup | N. Sattar | M. Sandhu | P. Harst | D. Rothenbacher | C. Nelson | A. Hamsten | A. Franco‐Cereceda | P. Eriksson | H. Nathoe | M. Scholz | D. Morrow | J. Verschuren | J. Pitha | W. Spiering | H. Watkins | I. Day | S. Mehta | A. Goel | L. Folkersen | F. Veglia | M. Trip | J. Price | K. Khaw | D. Baldassarre | E. Tremoli | M. Kumari | G. Hovingh | M. Kivimaki | G. Navis | J. Jukema | G. Paré | J. Casas | K. Fox | S. Boekholdt | I. M. Leach | S. Trompet | I. Ford | R. Gansevoort | F. Asselbergs | A. Tybjaerg-hansen | U. Faire | M. Holmes | R. Morris | L. Holdt | D. Teupser | N. Onland-Moret | J. Cooper | J. Thiery | T. Palmer | B. Keating | N. Danchin | O. Klungel | T. Simon | T. Hooft | K. Kuchenbaecker | P. Knijff | M. Hofker | M. Leusink | A. Tedgui | J. Palmen | F. Beutner | A. Panayiotou | J. Hubacek | V. Adámková | Z. Mallat | S. Tsimikas | J. Stephens | K. Carruthers | G. Schwartz | E. V. Iperen | D. Swerdlow | J. C. Witteman | K. Brunisholz | L. Breitling | M. Cramer | D. Dallmeier | Kimberly D. Brunisholz | P. Doevendans | C. L. Haase | H. Exeter | R. Poledne | S. Kotti | E. Staines-Urias | F. van | Andrew Nicolaides | Albert Hofman | W. Koenig | H. Brenner | KarlGertow | Anders Olsson | Jaqueline C. M. Witteman | Steve E. Humphries | Jeffrey L. Anderson | Anders G. Olsson | A. Hofman | J. Piťha | A. Franco-Cereceda | A. Uitterlinden | J. Witteman | A. Goel | C. Nelson

[1]  Tom R. Gaunt,et al.  Secretory Phospholipase A2-IIA and Cardiovascular Disease , 2013, Journal of the American College of Cardiology.

[2]  R. Rosenson,et al.  Phospholipase A2 enzymes and the risk of atherosclerosis. , 2012, European heart journal.

[3]  A. Dominiczak,et al.  Genetic basis of blood pressure and hypertension. , 2012, Trends in genetics : TIG.

[4]  A. Tedgui,et al.  Phospholipase A2 Enzymes, High-Dose Atorvastatin, and Prediction of Ischemic Events After Acute Coronary Syndromes , 2012, Circulation.

[5]  J. Kastelein,et al.  Inhibition of Secretory Phospholipase A2 in Patients with Acute Coronary Syndromes: Rationale and Design of the Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks (VISTA-16) Trial , 2012, Cardiovascular Drugs and Therapy.

[6]  S. Solomon,et al.  Prognostic utility of secretory phospholipase A(2) in patients with stable coronary artery disease. , 2011, Clinical chemistry.

[7]  Christopher D. Brown,et al.  Identification, Replication, and Functional Fine-Mapping of Expression Quantitative Trait Loci in Primary Human Liver Tissue , 2011, PLoS genetics.

[8]  R. Rosenson,et al.  Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease. , 2011, European heart journal.

[9]  W. Cantor,et al.  The sPLA2 Inhibition to Decrease Enzyme Release After Percutaneous Coronary Intervention (SPIDER-PCI) Trial , 2010, Circulation.

[10]  G. Lambeau,et al.  Lipoprotein-Associated and Secreted Phospholipases A2 in Cardiovascular Disease: Roles as Biological Effectors and Biomarkers , 2010, Circulation.

[11]  D. Waters,et al.  Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients. , 2010, Journal of the American College of Cardiology.

[12]  Tanya M. Teslovich,et al.  Biological, Clinical, and Population Relevance of 95 Loci for Blood Lipids , 2010, Nature.

[13]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[14]  D. Waters,et al.  Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial , 2009, The Lancet.

[15]  Heather L Rick,et al.  Varespladib (A-002), a Secretory Phospholipase A2 Inhibitor, Reduces Atherosclerosis and Aneurysm Formation in ApoE−/− Mice , 2009, Journal of cardiovascular pharmacology.

[16]  George Davey Smith,et al.  Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology , 2008, Statistics in medicine.

[17]  D. Lawlor,et al.  Re: Estimation of bias in nongenetic observational studies using "Mendelian triangulation" by Bautista et al. , 2007, Annals of epidemiology.

[18]  R. Luben,et al.  Circulating Secretory Phospholipase A2 Activity and Risk of Incident Coronary Events in Healthy Men and Women: The EPIC-NORFOLK Study , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[19]  S. Humphries,et al.  Tagging-SNP haplotype analysis of the secretory PLA2IIa gene PLA2G2A shows strong association with serum levels of sPLA2IIa: results from the UDACS study. , 2006, Human molecular genetics.

[20]  B. Asselain,et al.  Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. , 2005, Journal of the American College of Cardiology.

[21]  D. Praticò,et al.  Macrophage-specific expression of group IIA sPLA2 results in accelerated atherogenesis by increasing oxidative stress Published, JLR Papers in Press, May 16, 2005. DOI 10.1194/jlr.M400469-JLR200 , 2005, Journal of Lipid Research.

[22]  N. Day,et al.  Serum Levels of Type II Secretory Phospholipase A2 and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women: The EPIC-Norfolk Prospective Population Study , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[23]  Keith R Abrams,et al.  An integrated approach to the meta-analysis of genetic association studies using Mendelian randomization. , 2004, American journal of epidemiology.

[24]  N. Roehm,et al.  Pharmacology of LY315920/S-5920, [[3-(aminooxoacetyl)-2-ethyl-1- (phenylmethyl)-1H-indol-4-yl]oxy] acetate, a potent and selective secretory phospholipase A2 inhibitor: A new class of anti-inflammatory drugs, SPI. , 1999, The Journal of pharmacology and experimental therapeutics.